Global Needle Free Diabetes Management 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI09244011

Publication Date:

September 6, 2024

Pages:

106

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Needle Free Diabetes Management market size was valued at US$ million in 2023. With growing demand in downstream market, the Needle Free Diabetes Management is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Needle Free Diabetes Management market. Needle Free Diabetes Management are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Needle Free Diabetes Management. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Needle Free Diabetes Management market.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Key Features:
The report on Needle Free Diabetes Management market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Needle Free Diabetes Management market. It may include historical data, market segmentation by Type (e.g., Insulin Jet Injector, Insulin Pen), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Needle Free Diabetes Management market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Needle Free Diabetes Management market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Needle Free Diabetes Management industry. This include advancements in Needle Free Diabetes Management technology, Needle Free Diabetes Management new entrants, Needle Free Diabetes Management new investment, and other innovations that are shaping the future of Needle Free Diabetes Management.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Needle Free Diabetes Management market. It includes factors influencing customer ' purchasing decisions, preferences for Needle Free Diabetes Management product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Needle Free Diabetes Management market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Needle Free Diabetes Management market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Needle Free Diabetes Management market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Needle Free Diabetes Management industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Needle Free Diabetes Management market.
麻豆原创 Segmentation:
Needle Free Diabetes Management market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Insulin Jet Injector
Insulin Pen
Insulin Inhaler
Insulin Patch & Pump
Segmentation by application
Hospitals
Clinics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Zogenix
3M
Antares Pharma Inc.
Glide Pharmaceutical Technologies
Injex Pharma AG
Pharmajet, Inc.
Bioject Medical Technologies
Medtronic
Johnson & Johnson
Pancreum LLC
Tandem Diabetes Care
JDRF
Akra Dermojet

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Needle Free Diabetes Management 麻豆原创 Size 2019-2030
2.1.2 Needle Free Diabetes Management 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Needle Free Diabetes Management Segment by Type
2.2.1 Insulin Jet Injector
2.2.2 Insulin Pen
2.2.3 Insulin Inhaler
2.2.4 Insulin Patch & Pump
2.3 Needle Free Diabetes Management 麻豆原创 Size by Type
2.3.1 Needle Free Diabetes Management 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Needle Free Diabetes Management 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Needle Free Diabetes Management Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Other
2.5 Needle Free Diabetes Management 麻豆原创 Size by Application
2.5.1 Needle Free Diabetes Management 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Needle Free Diabetes Management 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Needle Free Diabetes Management 麻豆原创 Size by Player
3.1 Needle Free Diabetes Management 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Needle Free Diabetes Management Revenue by Players (2019-2024)
3.1.2 Global Needle Free Diabetes Management Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Needle Free Diabetes Management Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Needle Free Diabetes Management by Regions
4.1 Needle Free Diabetes Management 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Needle Free Diabetes Management 麻豆原创 Size Growth (2019-2024)
4.3 APAC Needle Free Diabetes Management 麻豆原创 Size Growth (2019-2024)
4.4 Europe Needle Free Diabetes Management 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Needle Free Diabetes Management 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Needle Free Diabetes Management 麻豆原创 Size by Country (2019-2024)
5.2 Americas Needle Free Diabetes Management 麻豆原创 Size by Type (2019-2024)
5.3 Americas Needle Free Diabetes Management 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Needle Free Diabetes Management 麻豆原创 Size by Region (2019-2024)
6.2 APAC Needle Free Diabetes Management 麻豆原创 Size by Type (2019-2024)
6.3 APAC Needle Free Diabetes Management 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Needle Free Diabetes Management by Country (2019-2024)
7.2 Europe Needle Free Diabetes Management 麻豆原创 Size by Type (2019-2024)
7.3 Europe Needle Free Diabetes Management 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Needle Free Diabetes Management by Region (2019-2024)
8.2 Middle East & Africa Needle Free Diabetes Management 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Needle Free Diabetes Management 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Needle Free Diabetes Management 麻豆原创 Forecast
10.1 Global Needle Free Diabetes Management Forecast by Regions (2025-2030)
10.1.1 Global Needle Free Diabetes Management Forecast by Regions (2025-2030)
10.1.2 Americas Needle Free Diabetes Management Forecast
10.1.3 APAC Needle Free Diabetes Management Forecast
10.1.4 Europe Needle Free Diabetes Management Forecast
10.1.5 Middle East & Africa Needle Free Diabetes Management Forecast
10.2 Americas Needle Free Diabetes Management Forecast by Country (2025-2030)
10.2.1 United States Needle Free Diabetes Management 麻豆原创 Forecast
10.2.2 Canada Needle Free Diabetes Management 麻豆原创 Forecast
10.2.3 Mexico Needle Free Diabetes Management 麻豆原创 Forecast
10.2.4 Brazil Needle Free Diabetes Management 麻豆原创 Forecast
10.3 APAC Needle Free Diabetes Management Forecast by Region (2025-2030)
10.3.1 China Needle Free Diabetes Management 麻豆原创 Forecast
10.3.2 Japan Needle Free Diabetes Management 麻豆原创 Forecast
10.3.3 Korea Needle Free Diabetes Management 麻豆原创 Forecast
10.3.4 Southeast Asia Needle Free Diabetes Management 麻豆原创 Forecast
10.3.5 India Needle Free Diabetes Management 麻豆原创 Forecast
10.3.6 Australia Needle Free Diabetes Management 麻豆原创 Forecast
10.4 Europe Needle Free Diabetes Management Forecast by Country (2025-2030)
10.4.1 Germany Needle Free Diabetes Management 麻豆原创 Forecast
10.4.2 France Needle Free Diabetes Management 麻豆原创 Forecast
10.4.3 UK Needle Free Diabetes Management 麻豆原创 Forecast
10.4.4 Italy Needle Free Diabetes Management 麻豆原创 Forecast
10.4.5 Russia Needle Free Diabetes Management 麻豆原创 Forecast
10.5 Middle East & Africa Needle Free Diabetes Management Forecast by Region (2025-2030)
10.5.1 Egypt Needle Free Diabetes Management 麻豆原创 Forecast
10.5.2 South Africa Needle Free Diabetes Management 麻豆原创 Forecast
10.5.3 Israel Needle Free Diabetes Management 麻豆原创 Forecast
10.5.4 Turkey Needle Free Diabetes Management 麻豆原创 Forecast
10.5.5 GCC Countries Needle Free Diabetes Management 麻豆原创 Forecast
10.6 Global Needle Free Diabetes Management Forecast by Type (2025-2030)
10.7 Global Needle Free Diabetes Management Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Zogenix
11.1.1 Zogenix Company Information
11.1.2 Zogenix Needle Free Diabetes Management Product Offered
11.1.3 Zogenix Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Zogenix Main Business Overview
11.1.5 Zogenix Latest Developments
11.2 3M
11.2.1 3M Company Information
11.2.2 3M Needle Free Diabetes Management Product Offered
11.2.3 3M Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 3M Main Business Overview
11.2.5 3M Latest Developments
11.3 Antares Pharma Inc.
11.3.1 Antares Pharma Inc. Company Information
11.3.2 Antares Pharma Inc. Needle Free Diabetes Management Product Offered
11.3.3 Antares Pharma Inc. Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Antares Pharma Inc. Main Business Overview
11.3.5 Antares Pharma Inc. Latest Developments
11.4 Glide Pharmaceutical Technologies
11.4.1 Glide Pharmaceutical Technologies Company Information
11.4.2 Glide Pharmaceutical Technologies Needle Free Diabetes Management Product Offered
11.4.3 Glide Pharmaceutical Technologies Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Glide Pharmaceutical Technologies Main Business Overview
11.4.5 Glide Pharmaceutical Technologies Latest Developments
11.5 Injex Pharma AG
11.5.1 Injex Pharma AG Company Information
11.5.2 Injex Pharma AG Needle Free Diabetes Management Product Offered
11.5.3 Injex Pharma AG Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Injex Pharma AG Main Business Overview
11.5.5 Injex Pharma AG Latest Developments
11.6 Pharmajet, Inc.
11.6.1 Pharmajet, Inc. Company Information
11.6.2 Pharmajet, Inc. Needle Free Diabetes Management Product Offered
11.6.3 Pharmajet, Inc. Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Pharmajet, Inc. Main Business Overview
11.6.5 Pharmajet, Inc. Latest Developments
11.7 Bioject Medical Technologies
11.7.1 Bioject Medical Technologies Company Information
11.7.2 Bioject Medical Technologies Needle Free Diabetes Management Product Offered
11.7.3 Bioject Medical Technologies Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Bioject Medical Technologies Main Business Overview
11.7.5 Bioject Medical Technologies Latest Developments
11.8 Medtronic
11.8.1 Medtronic Company Information
11.8.2 Medtronic Needle Free Diabetes Management Product Offered
11.8.3 Medtronic Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Medtronic Main Business Overview
11.8.5 Medtronic Latest Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Information
11.9.2 Johnson & Johnson Needle Free Diabetes Management Product Offered
11.9.3 Johnson & Johnson Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Johnson & Johnson Main Business Overview
11.9.5 Johnson & Johnson Latest Developments
11.10 Pancreum LLC
11.10.1 Pancreum LLC Company Information
11.10.2 Pancreum LLC Needle Free Diabetes Management Product Offered
11.10.3 Pancreum LLC Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Pancreum LLC Main Business Overview
11.10.5 Pancreum LLC Latest Developments
11.11 Tandem Diabetes Care
11.11.1 Tandem Diabetes Care Company Information
11.11.2 Tandem Diabetes Care Needle Free Diabetes Management Product Offered
11.11.3 Tandem Diabetes Care Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Tandem Diabetes Care Main Business Overview
11.11.5 Tandem Diabetes Care Latest Developments
11.12 JDRF
11.12.1 JDRF Company Information
11.12.2 JDRF Needle Free Diabetes Management Product Offered
11.12.3 JDRF Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 JDRF Main Business Overview
11.12.5 JDRF Latest Developments
11.13 Akra Dermojet
11.13.1 Akra Dermojet Company Information
11.13.2 Akra Dermojet Needle Free Diabetes Management Product Offered
11.13.3 Akra Dermojet Needle Free Diabetes Management Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Akra Dermojet Main Business Overview
11.13.5 Akra Dermojet Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.